ORIGINAL ARTICLESImprovement in cognitive abilities following cabergoline treatment in patients with a prolactin-secreting pituitary adenomaMontalvo, Itziara; Llorens, Martaa; Caparrós, Laiaa; Pamias, Montserrata; Torralbas, Jordia; Giménez-Palop, Olgab; Caixàs, Assumptab; Palao, Diego J.a; Labad, Javiera Author Information Departments of aMental Health, CIBERSAM bEndocrinology, Corporació Sanitària Parc Taulí, Sabadell, Spain Correspondence to Javier Labad, MD, PhD, Department of Mental Health, Parc Taulí Hospital Universitari, CIBERSAM, 08208 Sabadell, Spain Tel: +34 93 723 1010; fax: +34 93 723 7181; e-mail: [email protected] Received June 16, 2017 Accepted August 17, 2017 International Clinical Psychopharmacology: March 2018 - Volume 33 - Issue 2 - p 98-102 doi: 10.1097/YIC.0000000000000199 Buy Metrics Abstract Hyperprolactinaemia may affect sexual and reproductive functioning. However, recent studies suggest that increased prolactin levels may also have negative effects on cognition. We aimed to study whether the reduction in prolactin levels by cabergoline in patients with hyperprolactinaemia is followed by an improvement in cognitive tasks. We studied seven patients with hyperprolactinaemia caused by a prolactinoma that had an indication to start treatment with cabergoline. All patients were assessed twice (baseline and 6–12 months after cabergoline treatment) with a cognitive battery. Plasma prolactin levels were determined. We found a significant improvement in the speed of processing, working memory, visual learning and reasoning and problem-solving domains after cabergoline treatment. Improvements in speed of processing and reasoning and problem solving were greater in patients with baseline prolactin levels above the median. In summary, a reduction in prolactin levels by cabergoline in patients with hyperprolactinaemia is followed by an improvement in cognitive abilities. This finding suggests that prolactin may be involved in cognitive processes, although cabergoline could also have procognitive effects that are independent of prolactin changes. Further clinical trials are needed to confirm the potential cognitive-enhancement properties of cabergoline in patients with chronic hyperprolactinaemia. Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.